Aravive Balance Sheet Health
Financial Health criteria checks 1/6
Aravive has a total shareholder equity of $-19.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $25.7M and $45.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$18.36m |
| Equity | -US$19.82m |
| Total liabilities | US$45.55m |
| Total assets | US$25.74m |
Recent financial health updates
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Apr 26
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Sep 03We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully
May 15Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Nov 06Recent updates
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Apr 26Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Sep 03Aravive Q2 GAAP EPS misses, revenue beats
Aug 11Aravive appoints Robert Geller as CMO
Jul 05We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully
May 15Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Nov 06Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Jun 25Aravive EPS beats by $0.01, misses on revenue
May 06Aravive shares rise after dosing first patient in late-stage ovarian cancer study
Apr 27Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?
Mar 18Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Feb 09
Aravive: Pipeline-In-A-Pill In Oncology
Dec 28Aravive (ARAV) Investor Presentation - Slideshow
Dec 04Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative
Nov 19Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China
Nov 10Financial Position Analysis
Short Term Liabilities: ARAV has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ARAV has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ARAV is debt free.
Reducing Debt: ARAV's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARAV has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ARAV has less than a year of cash runway if free cash flow continues to grow at historical rates of 10% each year.